Natriuretic Peptides: The Case of Prostate Cancer
Open Access
Abstract
Cardiac natriuretic peptides have long been known to act as main players in the homeostatic control of blood pressure, salt and water balance. However, in the last few decades, new properties have been ascribed to these hormones. A systematic review of English articles using MEDLINE Search terms included prostate cancer, inflammation, cardiac hormones, atrial natriuretic peptide, and brain natriuretic peptide. Most recent publications were selected. Natriuretic peptides are strongly connected to the immune system, whose two branches, innate and adaptive, are finely tuned and organized to kill invaders and repair injured tissues. These peptides control the immune response and act as anti-inflammatory and immune-modulatory agents. In addition, in cancers, natriuretic peptides have anti-proliferative effects by molecular mechanisms based on the inhibition/regulation of several pathways promoting cell proliferation and survival. Nowadays, it is accepted that chronic inflammation is a crucial player in prostate cancer development and progression. In this review, we summarize the current knowledge on the link between prostate cancer and inflammation and the potential use of natriuretic peptides as anti-inflammatory and anticancer agents.Keywords
Funding Information
- Fondazione Cassa di Risparmio, Perugia (2015.0326.021)
This publication has 111 references indexed in Scilit:
- Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: Results from the REDUCE studyCancer, 2013
- Glyoxalase 1−419C>A Variant Is Associated with Oxidative Stress: Implications in Prostate Cancer ProgressionPLOS ONE, 2013
- 67-kDa laminin receptor increases cGMP to induce cancer-selective apoptosisJournal of Clinical Investigation, 2013
- Physiology and clinical significance of natriuretic hormonesIndian Journal of Endocrinology and Metabolism, 2013
- Association of the Innate Immunity and Inflammation Pathway with Advanced Prostate Cancer RiskPLOS ONE, 2012
- The NLRP3 inflammasome in health and disease: the good, the bad and the uglyClinical and Experimental Immunology, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- Natriuretic Peptide Receptor A as a Novel Target for Prostate CancerMolecular Cancer, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Inflammation in prostate carcinogenesisNature Reviews Cancer, 2007